페길화 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The PEGylation Market size is expected to reach USD 7.72 Billion in 2034 from USD 2.72 Billion (2025) growing at a CAGR of 12.3% during 2026-2034.

The global PEGylation market is witnessing rapid growth due to its increasing application in drug development and biotechnology. PEGylation involves attaching polyethylene glycol (PEG) chains to molecules, enhancing drug stability, solubility, and circulation time in the body. The growing demand for biologics and targeted therapies is a key factor driving market expansion. Additionally, advancements in pharmaceutical research are supporting the development of PEGylated drugs for various medical conditions.

Key growth drivers include the rising focus on improving drug efficacy and reducing side effects. PEGylation technology is widely used in the development of protein-based drugs and therapeutics. The expansion of the biopharmaceutical industry and increasing investments in research and development are also contributing to market growth. Furthermore, the growing adoption of personalized medicine is boosting demand for advanced drug delivery technologies.

In the future, the PEGylation market is expected to grow significantly with continuous innovation in biotechnology and pharmaceutical sciences. The development of next-generation PEGylation techniques will further enhance drug performance. Emerging markets are likely to offer strong growth opportunities due to increasing investments in healthcare and biotechnology. Additionally, ongoing research into novel therapeutic applications will continue to drive market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product & Services

• Consumables
• Services

By Protein Type

• Colony-stimulating Factor
• Interferons
• Erythropoietin
• Recombinant Factor VII
• Others

By Application

• Cancer
• Autoimmune Diseases
• Hepatitis
• Multiple Sclerosis
• Hemophilia
• Gastrointestinal Disorders
• Others

By End-user

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic & Research Institutes

COMPANIES PROFILED

• Thermo Fisher Scientific Inc, Abcam plc, Enzon Pharmaceuticals Inc, Merck KGaA, Celares GmbH, Profacgen, Creative PEGworks, NOF America Corp, Aurigene Pharmaceutical Services Ltd, Laysan Bio Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PEGYLATION MARKET: BY PRODUCT & SERVICES 2022-2034 (USD MN and Tons)

• 4.1. Market Analysis, Insights and Forecast Product & Services
• 4.2. Consumables Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
• 4.3. Services Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)

Chapter 5. GLOBAL PEGYLATION MARKET: BY PROTEIN TYPE 2022-2034 (USD MN and Tons)

• 5.1. Market Analysis, Insights and Forecast Protein Type
• 5.2. Colony-stimulating Factor Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
• 5.3. Interferons Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
• 5.4. Erythropoietin Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
• 5.5. Recombinant Factor VII Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)

Chapter 6. GLOBAL PEGYLATION MARKET: BY APPLICATION 2022-2034 (USD MN and Tons)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
• 6.3. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
• 6.4. Hepatitis Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
• 6.5. Multiple Sclerosis Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
• 6.6. Hemophilia Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
• 6.7. Gastrointestinal Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
• 6.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)

Chapter 7. GLOBAL PEGYLATION MARKET: BY END-USER 2022-2034 (USD MN and Tons)

• 7.1. Market Analysis, Insights and Forecast End-user
• 7.2. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
• 7.3. Contract Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)
• 7.4. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN and Tons)

Chapter 8. GLOBAL PEGYLATION MARKET: BY REGION 2022-2034 (USD MN and Tons)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Tons)
  • 8.2.1 By Product & Services
  • 8.2.2 By Protein Type
  • 8.2.3 By Application
  • 8.2.4 By End-user
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Tons)
  • 8.3.1 By Product & Services
  • 8.3.2 By Protein Type
  • 8.3.3 By Application
  • 8.3.4 By End-user
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Tons)
  • 8.4.1 By Product & Services
  • 8.4.2 By Protein Type
  • 8.4.3 By Application
  • 8.4.4 By End-user
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Tons)
  • 8.5.1 By Product & Services
  • 8.5.2 By Protein Type
  • 8.5.3 By Application
  • 8.5.4 By End-user
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Tons)
  • 8.6.1 By Product & Services
  • 8.6.2 By Protein Type
  • 8.6.3 By Application
  • 8.6.4 By End-user
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PEGYLATION INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Thermo Fisher Scientific Inc
  • 10.2.2 Abcam Plc
  • 10.2.3 Enzon Pharmaceuticals Inc
  • 10.2.4 Merck KGaA
  • 10.2.5 Celares GmbH
  • 10.2.6 Profacgen
  • 10.2.7 Creative PEGworks
  • 10.2.8 NOF America Corp
  • 10.2.9 Aurigene Pharmaceutical Services Ltd
  • 10.2.10 Laysan Bio Inc